xeneticbio.com - רווח תפעולי EBITDA XBIO

Xenetic Biosciences (XBIO) develops targeted drugs against dangerous tumors, leveraging patents and licensing agreements with pharmaceutical behemoths. An innovative method of disrupting the cancer's protective barrier using enzymes exponentially enhances the impact of chemotherapy. Royalties support the company's stability, offsetting the risks associated with early clinical trials. Data from the GURU.Markets terminal provides a fixed EBITDA level, where the value is recorded at 0.00.
Xenetic Biosciences, Inc. (XBIO) - פילוחי מדדים ודוחות פיננסיים

Absolute operating profit measures a business's ability to generate cash flow before depreciation and interest, which is critical for assessing solvency during a period of high interest rates. The current EBITDA_Co level on this chart is 0.00, reflecting the efficiency of the Xenetic Biosciences (XBIO) scientific platform and its clinic partnerships in sustaining oncology drug development amid expensive financing.